H-CYTE, Inc. (HCYT)
Stock Price: $0.0413 USD
0.0003 (0.73%)
Updated Jul 30, 2021 3:16 PM EDT - Market closed
| Market Cap | 5.97M |
| Revenue (ttm) | 1.51M |
| Net Income (ttm) | -5.63M |
| Shares Out | 144.43M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $0.0413 |
| Previous Close | $0.0410 |
| Change ($) | 0.0003 |
| Change (%) | 0.73% |
| Day's Open | 0.0444 |
| Day's Range | 0.0412 - 0.0480 |
| Day's Volume | 103,916 |
| 52-Week Range | 0.0060 - 0.1500 |
News
There are no news available yet.
About HCYT
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute biologics for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
| Industry Medical Devices | |
| Stock Exchange OTCMKTS | Ticker Symbol HCYT |
Financial Performance
In 2020, H-CYTE, Inc.'s revenue was $2.15 million, a decrease of -74.23% compared to the previous year's $8.35 million. Losses were -$6.46 million, -78.33% less than in 2019.